Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (461)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
31
2022
427
4.060
 Why?
Hyperkalemia
4
2021
35
2.490
 Why?
Everolimus
10
2016
111
2.300
 Why?
Health Resources
9
2022
129
2.230
 Why?
Cost of Illness
13
2022
321
1.990
 Why?
Health Services
11
2016
115
1.470
 Why?
Breast Neoplasms
16
2018
2452
1.450
 Why?
Antineoplastic Agents
20
2018
2194
1.420
 Why?
Citalopram
6
2012
32
1.200
 Why?
Receptors, Antigen, T-Cell
4
2021
668
1.130
 Why?
Health Expenditures
9
2020
194
1.120
 Why?
Receptors, Estrogen
3
2015
457
1.100
 Why?
Medication Adherence
4
2015
539
1.040
 Why?
Psoriasis
5
2018
112
1.000
 Why?
Immunotherapy, Adoptive
2
2020
337
0.980
 Why?
Insurance Claim Review
18
2017
83
0.960
 Why?
Practice Patterns, Physicians'
6
2018
1356
0.950
 Why?
United States
52
2022
15966
0.930
 Why?
Hepatitis C, Chronic
3
2019
152
0.910
 Why?
Pyrimidines
7
2014
532
0.880
 Why?
Renal Insufficiency, Chronic
3
2021
653
0.870
 Why?
Drug Substitution
3
2019
63
0.860
 Why?
Piperazines
6
2014
381
0.860
 Why?
Biosimilar Pharmaceuticals
2
2022
28
0.850
 Why?
Middle Aged
75
2020
35875
0.850
 Why?
Attention Deficit Disorder with Hyperactivity
4
2012
428
0.790
 Why?
Receptors, Progesterone
2
2015
356
0.790
 Why?
Models, Economic
2
2020
62
0.770
 Why?
Aged
56
2022
25913
0.770
 Why?
Retrospective Studies
45
2022
17066
0.760
 Why?
Comparative Effectiveness Research
3
2012
170
0.760
 Why?
Benzamides
6
2014
224
0.750
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
2014
127
0.740
 Why?
Antifungal Agents
4
2017
149
0.730
 Why?
Humans
122
2022
144759
0.720
 Why?
Cost-Benefit Analysis
15
2022
634
0.720
 Why?
Imatinib Mesylate
7
2014
77
0.710
 Why?
Female
92
2021
78271
0.700
 Why?
Central Nervous System Stimulants
3
2012
185
0.690
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
192
0.670
 Why?
Hospital Costs
3
2020
124
0.670
 Why?
Gout
2
2012
35
0.660
 Why?
Rheumatology
1
2022
133
0.650
 Why?
Acidosis
1
2021
105
0.640
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
293
0.630
 Why?
Adult
57
2022
40449
0.630
 Why?
Male
78
2021
72315
0.630
 Why?
Proportional Hazards Models
14
2017
1325
0.630
 Why?
Hypoglycemic Agents
4
2015
1387
0.620
 Why?
Kaplan-Meier Estimate
12
2018
965
0.620
 Why?
Nocturia
1
2019
8
0.620
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2018
1953
0.600
 Why?
Antibodies, Monoclonal
7
2018
1519
0.600
 Why?
Databases, Factual
13
2021
1486
0.590
 Why?
Prevalence
11
2021
2834
0.590
 Why?
Postmenopause
7
2018
391
0.580
 Why?
Hospitalization
15
2021
2433
0.560
 Why?
Comorbidity
12
2014
1658
0.550
 Why?
Medicare
10
2022
886
0.550
 Why?
Nutrition Surveys
1
2019
282
0.540
 Why?
Proline
2
2015
83
0.530
 Why?
Candida
2
2017
44
0.530
 Why?
Leukemia, Myeloid, Chronic-Phase
2
2014
3
0.520
 Why?
Fluconazole
1
2017
23
0.520
 Why?
Protein Kinase Inhibitors
5
2014
969
0.510
 Why?
Candidemia
1
2017
15
0.510
 Why?
Cardiologists
1
2017
47
0.500
 Why?
Myocardial Perfusion Imaging
1
2017
49
0.500
 Why?
Fees, Pharmaceutical
3
2016
8
0.500
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
103
0.500
 Why?
Oligopeptides
2
2015
269
0.490
 Why?
Aftercare
2
2021
223
0.480
 Why?
Thrombolytic Therapy
1
2017
163
0.470
 Why?
Diabetes Mellitus, Type 2
5
2015
2583
0.470
 Why?
Cystitis, Interstitial
2
2006
20
0.470
 Why?
Biological Therapy
1
2016
28
0.470
 Why?
Antidepressive Agents, Second-Generation
3
2011
44
0.470
 Why?
Antiviral Agents
3
2019
767
0.460
 Why?
Antirheumatic Agents
2
2016
304
0.460
 Why?
Drug Eruptions
1
2015
28
0.450
 Why?
Tissue Plasminogen Activator
1
2017
244
0.450
 Why?
Propylamines
2
2012
11
0.440
 Why?
Costs and Cost Analysis
10
2019
219
0.430
 Why?
Fibrinolytic Agents
1
2017
291
0.430
 Why?
Physicians, Primary Care
1
2017
207
0.430
 Why?
Gastrointestinal Stromal Tumors
1
2014
40
0.420
 Why?
Methylphenidate
2
2012
49
0.420
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
338
0.420
 Why?
Diphosphonates
2
2012
68
0.420
 Why?
Delivery of Health Care
2
2019
947
0.420
 Why?
Health Care Rationing
2
2016
59
0.420
 Why?
Insulin
3
2015
2507
0.410
 Why?
Anemia
1
2015
188
0.400
 Why?
Brain Ischemia
1
2017
358
0.400
 Why?
Treatment Outcome
24
2021
11679
0.400
 Why?
Imidazoles
2
2012
254
0.390
 Why?
Insurance, Health
5
2011
302
0.390
 Why?
Hypertension
5
2018
1263
0.390
 Why?
Neoplasm Metastasis
8
2018
688
0.390
 Why?
Dextroamphetamine
1
2012
4
0.370
 Why?
Aged, 80 and over
14
2020
8265
0.370
 Why?
Guanfacine
1
2012
5
0.370
 Why?
Antineoplastic Agents, Hormonal
4
2016
194
0.370
 Why?
Pharmacoepidemiology
1
2012
22
0.370
 Why?
Liver Neoplasms
2
2015
780
0.360
 Why?
Attention Deficit and Disruptive Behavior Disorders
1
2012
56
0.350
 Why?
Schizophrenia
2
2006
446
0.350
 Why?
Patient Compliance
3
2011
588
0.350
 Why?
Medicaid
3
2012
461
0.350
 Why?
Pulmonary Embolism
1
2014
244
0.340
 Why?
Drug Delivery Systems
1
2015
380
0.340
 Why?
Drug Costs
6
2015
116
0.340
 Why?
Fumarates
1
2011
10
0.340
 Why?
Disease-Free Survival
7
2019
769
0.340
 Why?
Antibodies, Monoclonal, Humanized
9
2018
985
0.330
 Why?
Drugs, Generic
1
2011
27
0.330
 Why?
Referral and Consultation
1
2017
851
0.330
 Why?
Bone Diseases
1
2011
61
0.320
 Why?
Amides
1
2011
101
0.320
 Why?
Triazoles
4
2016
184
0.310
 Why?
Angiotensin Receptor Antagonists
1
2011
114
0.310
 Why?
Neoplasm Recurrence, Local
3
2015
1137
0.310
 Why?
Stroke
2
2017
1256
0.310
 Why?
Drug Monitoring
4
2016
395
0.300
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
221
0.300
 Why?
Venous Thromboembolism
1
2014
324
0.300
 Why?
Arthritis, Rheumatoid
2
2016
1169
0.300
 Why?
Tumor Necrosis Factor-alpha
5
2022
1217
0.300
 Why?
Potassium
2
2021
152
0.300
 Why?
Sick Leave
2
2007
16
0.290
 Why?
Crohn Disease
5
2012
260
0.290
 Why?
Heart Failure
3
2020
2323
0.290
 Why?
Hyperuricemia
1
2009
47
0.290
 Why?
Diabetes Mellitus
1
2018
1098
0.290
 Why?
Myelodysplastic Syndromes
2
2021
147
0.290
 Why?
Anticoagulants
1
2014
722
0.280
 Why?
Oligonucleotides
2
2019
151
0.280
 Why?
Absenteeism
2
2005
53
0.270
 Why?
Uric Acid
1
2009
166
0.270
 Why?
Quality of Life
9
2021
3185
0.270
 Why?
Risk Factors
12
2017
10779
0.270
 Why?
Multiple Myeloma
1
2011
291
0.260
 Why?
Insurance Claim Reporting
2
2007
25
0.260
 Why?
Patient Acceptance of Health Care
7
2021
885
0.260
 Why?
Randomized Controlled Trials as Topic
3
2012
1720
0.250
 Why?
Physicians
1
2015
939
0.250
 Why?
Head and Neck Neoplasms
1
2012
558
0.250
 Why?
Hypoglycemia
1
2012
477
0.250
 Why?
Health Status Indicators
1
2007
166
0.250
 Why?
Drug Therapy, Combination
6
2019
1047
0.240
 Why?
Pentosan Sulfuric Polyester
1
2006
2
0.240
 Why?
Economics, Pharmaceutical
1
2006
10
0.240
 Why?
Drug Resistance, Fungal
2
2017
7
0.230
 Why?
Treatment Failure
3
2017
365
0.230
 Why?
Endometriosis
2
2017
57
0.230
 Why?
Young Adult
13
2020
14105
0.220
 Why?
Urinary Incontinence
1
2005
64
0.220
 Why?
Diagnostic Errors
1
2006
175
0.210
 Why?
Prostatic Neoplasms
2
2012
974
0.210
 Why?
Nitriles
3
2016
205
0.210
 Why?
Immunoglobulin G
1
2008
893
0.210
 Why?
Adolescent
21
2017
22428
0.210
 Why?
Recurrence
3
2020
1135
0.200
 Why?
Emergency Service, Hospital
4
2021
2310
0.200
 Why?
Electronic Health Records
2
2021
1173
0.200
 Why?
Protein-Tyrosine Kinases
4
2014
433
0.190
 Why?
Antihypertensive Agents
3
2012
510
0.190
 Why?
Psychotic Disorders
1
2005
186
0.190
 Why?
Molecular Targeted Therapy
3
2015
432
0.190
 Why?
Genetic Therapy
2
2021
313
0.180
 Why?
Infliximab
1
2022
108
0.180
 Why?
Delayed-Action Preparations
3
2017
183
0.180
 Why?
Thiophenes
2
2014
128
0.180
 Why?
Population Surveillance
1
2005
485
0.180
 Why?
Anti-Inflammatory Agents
3
2011
474
0.170
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
8
0.170
 Why?
Bone Density Conservation Agents
2
2012
81
0.170
 Why?
Gastritis
1
2022
115
0.170
 Why?
Gout Suppressants
2
2012
20
0.170
 Why?
Enteritis
1
2022
103
0.170
 Why?
Carcinoma, Non-Small-Cell Lung
3
2015
1180
0.170
 Why?
Biological Products
2
2016
252
0.160
 Why?
Polymerase Chain Reaction
2
2014
1054
0.160
 Why?
Severity of Illness Index
6
2018
2925
0.160
 Why?
Hemophilia B
1
2021
66
0.160
 Why?
Antimetabolites, Antineoplastic
1
2021
105
0.160
 Why?
Atomoxetine Hydrochloride
2
2012
8
0.160
 Why?
Bronchodilator Agents
2
2011
182
0.160
 Why?
Adenocarcinoma
1
2007
928
0.160
 Why?
Time Factors
5
2017
7173
0.160
 Why?
Immunologic Factors
1
2022
255
0.150
 Why?
Voriconazole
2
2016
21
0.150
 Why?
Eosinophilia
1
2022
221
0.150
 Why?
National Health Programs
1
2019
23
0.150
 Why?
Regression Analysis
4
2012
1003
0.150
 Why?
Technology Assessment, Biomedical
1
2019
44
0.150
 Why?
Pulmonary Disease, Chronic Obstructive
3
2011
920
0.150
 Why?
Muscular Atrophy, Spinal
1
2019
25
0.150
 Why?
Aromatase Inhibitors
2
2018
75
0.150
 Why?
Hemophilia A
1
2021
147
0.150
 Why?
Patient Readmission
2
2017
758
0.150
 Why?
Atrial Fibrillation
1
2005
550
0.150
 Why?
Survival of Motor Neuron 1 Protein
1
2019
13
0.150
 Why?
Health Services Research
1
2021
396
0.150
 Why?
Spinal Muscular Atrophies of Childhood
1
2019
18
0.150
 Why?
Survival Analysis
4
2018
1382
0.150
 Why?
Multivariate Analysis
5
2015
1539
0.140
 Why?
Microbial Sensitivity Tests
2
2017
370
0.140
 Why?
Urologic Neoplasms
1
2018
31
0.140
 Why?
China
2
2021
269
0.140
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
691
0.140
 Why?
Europe
3
2019
412
0.140
 Why?
Aging
1
2009
1966
0.140
 Why?
Vital Capacity
2
2015
290
0.140
 Why?
Polystyrenes
1
2018
37
0.140
 Why?
Managed Care Programs
2
2010
138
0.140
 Why?
Time-to-Treatment
2
2017
243
0.140
 Why?
Antidepressive Agents
2
2011
248
0.130
 Why?
Chronic Disease
4
2014
1813
0.130
 Why?
4-Aminopyridine
1
2017
30
0.130
 Why?
Retreatment
1
2017
77
0.130
 Why?
Overweight
1
2022
609
0.130
 Why?
Thiazoles
2
2014
135
0.130
 Why?
Aspergillosis
1
2016
23
0.130
 Why?
Drug Administration Schedule
4
2013
779
0.130
 Why?
Chemotherapy, Adjuvant
2
2016
421
0.120
 Why?
Patient Preference
1
2019
224
0.120
 Why?
Abiraterone Acetate
1
2016
15
0.120
 Why?
Administration, Intravenous
1
2017
170
0.120
 Why?
Consumer Behavior
1
2017
69
0.120
 Why?
Hysterectomy
1
2017
137
0.120
 Why?
Administrative Claims, Healthcare
1
2016
28
0.120
 Why?
Mental Disorders
1
2005
1168
0.120
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
53
0.120
 Why?
Capecitabine
1
2016
57
0.120
 Why?
Prednisone
1
2016
221
0.110
 Why?
Trastuzumab
1
2016
118
0.110
 Why?
Disability Evaluation
1
2017
310
0.110
 Why?
Clinical Protocols
1
2017
282
0.110
 Why?
Androstadienes
1
2015
76
0.110
 Why?
Ki-1 Antigen
1
2015
7
0.110
 Why?
Patient Admission
1
2017
218
0.110
 Why?
International Classification of Diseases
1
2016
147
0.110
 Why?
Patient Discharge
1
2021
983
0.110
 Why?
Waiting Lists
1
2017
263
0.110
 Why?
Logistic Models
2
2014
2117
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
22
0.110
 Why?
Ribavirin
1
2015
80
0.110
 Why?
Drug Interactions
1
2016
398
0.110
 Why?
Ambulatory Care
3
2015
600
0.110
 Why?
Neoplasm Staging
2
2015
1462
0.110
 Why?
California
2
2006
475
0.100
 Why?
Carboplatin
1
2014
160
0.100
 Why?
International Normalized Ratio
1
2014
49
0.100
 Why?
Heparin, Low-Molecular-Weight
1
2014
36
0.100
 Why?
Amphotericin B
1
2014
37
0.100
 Why?
Cytogenetic Analysis
1
2013
33
0.100
 Why?
Japan
3
2021
143
0.100
 Why?
Recombinant Proteins
1
2017
1370
0.100
 Why?
Insurance, Health, Reimbursement
1
2014
96
0.100
 Why?
Leukemia, Myeloid, Acute
1
2021
682
0.100
 Why?
Cross-Sectional Studies
3
2019
5868
0.100
 Why?
Follow-Up Studies
5
2015
5408
0.100
 Why?
Models, Theoretical
1
2017
582
0.100
 Why?
Drug Prescriptions
1
2015
284
0.100
 Why?
Constipation
1
2014
98
0.100
 Why?
Morpholines
1
2014
128
0.100
 Why?
ErbB Receptors
2
2016
627
0.100
 Why?
Immunoconjugates
1
2015
132
0.100
 Why?
Paclitaxel
1
2014
255
0.100
 Why?
Receptor Protein-Tyrosine Kinases
1
2015
230
0.100
 Why?
Mycoses
1
2014
88
0.100
 Why?
Budgets
1
2012
14
0.100
 Why?
Recovery of Function
1
2017
707
0.100
 Why?
Drug Combinations
2
2011
390
0.090
 Why?
Hodgkin Disease
1
2015
171
0.090
 Why?
Warfarin
1
2014
170
0.090
 Why?
Allopurinol
1
2012
69
0.090
 Why?
Cohort Studies
5
2016
5960
0.090
 Why?
Adalimumab
5
2011
55
0.090
 Why?
Laparoscopy
1
2017
475
0.090
 Why?
Lisdexamfetamine Dimesylate
1
2012
8
0.090
 Why?
New Zealand
1
2012
54
0.090
 Why?
Gastrointestinal Diseases
1
2014
216
0.090
 Why?
Immunocompromised Host
1
2014
201
0.090
 Why?
Pyridines
1
2016
605
0.090
 Why?
Ethanolamines
1
2012
14
0.090
 Why?
Databases as Topic
2
2009
71
0.090
 Why?
Benzopyrans
1
2012
30
0.090
 Why?
Health Status
2
2008
836
0.090
 Why?
Clinical Trials as Topic
2
2019
1053
0.090
 Why?
Genetic Testing
1
2015
478
0.090
 Why?
Estradiol
1
2015
533
0.090
 Why?
Triple Negative Breast Neoplasms
1
2014
215
0.090
 Why?
Florida
1
2012
117
0.090
 Why?
Sulfonylurea Compounds
1
2012
51
0.090
 Why?
Multiple Sclerosis
1
2017
484
0.090
 Why?
Rivaroxaban
1
2014
267
0.090
 Why?
Pleural Effusion
1
2012
60
0.090
 Why?
Neurotransmitter Uptake Inhibitors
1
2011
3
0.090
 Why?
Surveys and Questionnaires
4
2021
6048
0.090
 Why?
Australia
1
2012
286
0.090
 Why?
Fractures, Spontaneous
1
2011
15
0.090
 Why?
North America
1
2012
310
0.090
 Why?
Cyclohexanols
1
2011
10
0.090
 Why?
Lung Neoplasms
2
2015
2637
0.090
 Why?
Hypercalcemia
1
2011
22
0.080
 Why?
Spinal Cord Compression
1
2011
22
0.080
 Why?
Nebulizers and Vaporizers
1
2011
62
0.080
 Why?
Child
6
2020
22633
0.080
 Why?
Cost Sharing
1
2011
20
0.080
 Why?
Adamantane
1
2011
17
0.080
 Why?
Efficiency
2
2011
103
0.080
 Why?
Sirolimus
1
2012
281
0.080
 Why?
Models, Statistical
2
2012
681
0.080
 Why?
Bone Diseases, Metabolic
1
2011
56
0.080
 Why?
Case-Control Studies
3
2014
3604
0.080
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2011
46
0.080
 Why?
Communication
1
2017
965
0.080
 Why?
Norepinephrine
1
2011
196
0.080
 Why?
Health Benefit Plans, Employee
2
2009
26
0.080
 Why?
Bone Neoplasms
1
2012
253
0.080
 Why?
Pyrazines
1
2011
92
0.080
 Why?
Pyrrolidines
1
2011
125
0.080
 Why?
Angiogenesis Inhibitors
1
2011
237
0.080
 Why?
Linear Models
1
2012
854
0.070
 Why?
Administration, Oral
1
2012
847
0.070
 Why?
Gastrointestinal Agents
1
2009
66
0.070
 Why?
Drug Utilization
1
2010
166
0.070
 Why?
Etanercept
1
2008
60
0.070
 Why?
Serotonin
1
2011
293
0.070
 Why?
Obesity
1
2022
3077
0.070
 Why?
Blood Chemical Analysis
1
2009
109
0.070
 Why?
Receptors, Tumor Necrosis Factor
1
2008
163
0.070
 Why?
Age Distribution
3
2015
403
0.070
 Why?
Depressive Disorder
1
2011
387
0.070
 Why?
Amphetamines
1
2007
6
0.070
 Why?
Adrenergic Uptake Inhibitors
1
2007
14
0.070
 Why?
Insurance, Pharmaceutical Services
1
2007
24
0.070
 Why?
Digestive System Surgical Procedures
1
2008
109
0.070
 Why?
Employment
2
2007
188
0.070
 Why?
Medical Audit
1
2007
77
0.060
 Why?
Quality-Adjusted Life Years
2
2022
121
0.060
 Why?
Age Factors
3
2015
3333
0.060
 Why?
Veterans Disability Claims
1
2006
4
0.060
 Why?
Disease Progression
4
2015
2847
0.060
 Why?
Algorithms
1
2014
1837
0.060
 Why?
Laboratories
1
2007
109
0.060
 Why?
Private Sector
1
2006
49
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Coronary Disease
1
2008
383
0.060
 Why?
Ischemic Attack, Transient
1
2006
71
0.060
 Why?
Metabolic Diseases
1
2007
114
0.060
 Why?
Hallucinations
1
2005
31
0.060
 Why?
Atrial Flutter
1
2005
45
0.060
 Why?
Asthma
2
2007
1767
0.050
 Why?
Double-Blind Method
4
2011
2029
0.050
 Why?
Area Under Curve
1
2005
330
0.050
 Why?
Administration, Inhalation
3
2011
574
0.050
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
232
0.050
 Why?
Adrenal Cortex Hormones
1
2007
478
0.050
 Why?
Dasatinib
2
2014
57
0.050
 Why?
Metabolic Syndrome
1
2007
354
0.050
 Why?
Anti-Asthmatic Agents
1
2006
251
0.050
 Why?
Data Collection
1
2006
633
0.050
 Why?
Colorectal Neoplasms
1
2011
845
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
541
0.050
 Why?
Body Weight
1
2007
976
0.050
 Why?
Lung
1
2015
4109
0.050
 Why?
Bevacizumab
2
2014
167
0.050
 Why?
Health Policy
1
2005
400
0.040
 Why?
Drug Resistance, Neoplasm
1
2007
881
0.040
 Why?
Diagnosis, Differential
1
2006
1489
0.040
 Why?
Interviews as Topic
1
2005
901
0.040
 Why?
Veterans
1
2013
1603
0.040
 Why?
Dose-Response Relationship, Drug
3
2011
2027
0.040
 Why?
Glucagon-Like Peptides
1
2022
70
0.040
 Why?
Information Storage and Retrieval
1
2021
121
0.040
 Why?
Infant
4
2019
10034
0.040
 Why?
Mental Health Services
1
2005
473
0.040
 Why?
Asia
1
2019
70
0.040
 Why?
Azacitidine
1
2021
156
0.040
 Why?
Remission Induction
2
2011
307
0.040
 Why?
France
1
2019
40
0.040
 Why?
Spain
1
2019
48
0.040
 Why?
Incidence
1
2006
2879
0.040
 Why?
Reproducibility of Results
1
2007
3409
0.040
 Why?
Italy
1
2019
113
0.040
 Why?
Germany
1
2019
138
0.040
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.030
 Why?
Sex Factors
2
2015
2112
0.030
 Why?
Neutropenia
1
2018
155
0.030
 Why?
Potassium Channel Blockers
1
2017
47
0.030
 Why?
Disease Management
2
2015
645
0.030
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Bayes Theorem
1
2019
433
0.030
 Why?
Veterans Health
1
2018
189
0.030
 Why?
Itraconazole
1
2016
7
0.030
 Why?
B-Lymphocytes
1
2020
876
0.030
 Why?
Antineoplastic Protocols
1
2014
6
0.030
 Why?
Utilization Review
1
2014
39
0.030
 Why?
Cardiovascular Diseases
1
2007
2168
0.030
 Why?
Early Diagnosis
1
2015
249
0.030
 Why?
Forced Expiratory Volume
1
2015
449
0.030
 Why?
Aspergillus
1
2014
18
0.030
 Why?
Hypothyroidism
1
2014
67
0.030
 Why?
Gene Rearrangement
1
2015
155
0.030
 Why?
Genes, abl
1
2013
4
0.030
 Why?
Cryptococcus
1
2014
16
0.030
 Why?
Medication Therapy Management
1
2014
73
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
62
0.030
 Why?
Peripheral Vascular Diseases
1
2014
104
0.030
 Why?
Mood Disorders
1
2014
140
0.020
 Why?
Socioeconomic Factors
1
2018
1326
0.020
 Why?
Drug Utilization Review
1
2013
61
0.020
 Why?
Myocardium
1
2018
939
0.020
 Why?
Propensity Score
1
2014
367
0.020
 Why?
Acute Disease
1
2015
1030
0.020
 Why?
Atenolol
1
2012
7
0.020
 Why?
Biopsy
1
2015
1075
0.020
 Why?
Nebivolol
1
2012
9
0.020
 Why?
Metoprolol
1
2012
26
0.020
 Why?
Propanolamines
1
2012
40
0.020
 Why?
Carbazoles
1
2012
56
0.020
 Why?
Risk
1
2014
911
0.020
 Why?
Decision Making
1
2019
975
0.020
 Why?
Matched-Pair Analysis
1
2011
37
0.020
 Why?
Nervous System Diseases
1
2014
284
0.020
 Why?
Duloxetine Hydrochloride
1
2011
10
0.020
 Why?
Venlafaxine Hydrochloride
1
2011
12
0.020
 Why?
Cetuximab
1
2011
111
0.020
 Why?
Sitagliptin Phosphate
1
2011
31
0.020
 Why?
Tablets
1
2010
41
0.020
 Why?
State Medicine
1
2009
27
0.020
 Why?
Length of Stay
1
2015
1337
0.020
 Why?
Epidemiologic Methods
1
2009
89
0.020
 Why?
Critical Care
1
2015
695
0.020
 Why?
Injections, Subcutaneous
1
2009
164
0.020
 Why?
Blood Glucose
2
2011
2327
0.020
 Why?
Insurance Coverage
1
2010
239
0.020
 Why?
Maximum Tolerated Dose
1
2009
212
0.020
 Why?
United Kingdom
1
2009
338
0.020
 Why?
Odds Ratio
1
2011
1075
0.020
 Why?
Probability
1
2009
310
0.020
 Why?
Statistics, Nonparametric
1
2009
427
0.020
 Why?
Confidence Intervals
1
2008
333
0.020
 Why?
Canada
1
2009
428
0.020
 Why?
Reference Values
1
2009
797
0.020
 Why?
Sex Distribution
1
2008
386
0.020
 Why?
Longitudinal Studies
1
2014
2947
0.020
 Why?
Prognosis
1
2015
4282
0.020
 Why?
Models, Biological
1
2014
1821
0.010
 Why?
Analysis of Variance
1
2009
1306
0.010
 Why?
RNA, Messenger
1
2013
2832
0.010
 Why?
Tomography, X-Ray Computed
1
2015
2730
0.010
 Why?
Health Status Disparities
1
2008
321
0.010
 Why?
Child, Preschool
2
2007
11787
0.010
 Why?
Emergency Medical Services
1
2007
696
0.010
 Why?
Risk Assessment
1
2009
3671
0.010
 Why?
Body Mass Index
1
2007
2438
0.010
 Why?
Infant, Newborn
1
2006
6429
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (461) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)